For years, Total Value Locked (TVL) has been the canary in DeFi's coalmine. When it was up, the sector was ‘thriving'. When it was down, DeFi was ‘in decline'. During 2025, that narrative began to ...

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

One of the most detailed 3D maps of how the human chromosomes are organized and folded within a cell's nucleus is published ...

If you've been planning to step up your data science game for the new year, the 2026 NPTEL course lineup from India's top IITs is honestly a goldmine. These courses cover the backbone of modern ...

In 2025, large language models moved beyond benchmarks to efficiency, reliability, and integration, reshaping how AI is ...